ERGOMEDS's approach to clinical
research ensures effective patient
recruitment reducing time and cost
of clinical trials.

Our expertise and depth of experience in the clinical development process complements the drug discovery and development capabilities of our partners.

ERGOMED has a dual business model offering standard clinical trial management contracts and also co-development partnerships to share the risk and rewards of clinical development.

May, 06, 2009 - Ergomed Signs Co-Development Collaboration Agreement with Genzyme Corporation to Develop Tasidotin in Oncology. [read more]

February, 03, 2009 - PrimeVigilance – a new company has been formed and has already commenced trading. [read more]

January, 15, 2009 - ERGOMED appointed preferred provider to Light Sciences
Oncology (LSO). [read more]


[more News]

Bio-Europe Spring 2010, Barcelona
March 8-10, 2010

BioTrinity 2010, Newbury (UK)
April 12-14, 2010




[more Events]